A shadow market for unlicensed weight-loss drugs is being driven by social media fitness personalities and vendors on messaging platforms, based on new investigations.
Experimental Treatment Acquiring Traction Via Social Media
The experimental drug, which is still in clinical trials, is being advertised by social media influencers for its alleged fat-burning properties. Followers are urged to contact these profiles privately for source information, while also receiving promotional offers.
Thriving Trade on Messaging Platforms
Additionally, a flourishing market exists on messaging services, where communities with thousands of members share comparison photos, injection guides and claims of rapid British shipping. Sellers promote the substance there before directing customers to WhatsApp for transactions.
Understanding The Experimental Drug
This medication is an experimental injection developed by US drugmaker Eli Lilly. The treatment affects three intestinal hormones – glucagon-like peptide-1, GIP and pancreatic hormone. Preliminary studies indicate it could assist patients reduce up to a quarter of their body weight. Referred to as the “triple G”, the substance is being promoted digitally as the successor to Ozempic.
Medical Professionals Voice Concerns
Nevertheless, doctors and pharmacists have warned that the distribution of what remains an unapproved medication in the United Kingdom is a cause for concern and could lead to users injecting products of unknown origin.
Some experts stated the popularity for retatrutide could be connected to the increasing price of approved slimming products such as Mounjaro.
Regulatory Status and Implementation
Selling the unapproved drug on TikTok or Telegram is prohibited in the United Kingdom, as it is an unlicensed drug that must not be marketed or supplied for personal consumption under the Human Medicines Regulations 2012.
Several content creators try to circumvent the rules by referring to the substance as a “research chemical” or citing it as “not for human consumption”. Retatrutide is not a controlled drug, but promotion and distribution can still violate medicines, marketing, and customer regulations, risking fines, prosecution or prison.
Platform Reaction and Content Elimination
Based on the social media company, the service has taken down problematic material and banned associated keywords and search suggestions. The organization said it was dedicated to keeping the service safe and allocating resources in enhancing enforcement strategies.
Online Marketplace Activities
Investigations also found groups with up to nine thousand participants marketing retatrutide using the platform's built-in search feature, which operates like a online catalog. Entering “retatrutide” instantly brings up groups with thousands of members, filled with photos of slimming results, glowing reviews and step-by-step guides for mixing or injecting at residence.
Within moments of joining one group, a seller shared contact information, where most transactions occur. The vendor sent an instruction manual and promised delivery within two days. When questioned whether the substance was authentic, one seller said: “You can’t be sure.” Another shared a image of a supposed testing documentation. Not one inquired about body mass, medical conditions or previous experience.
Product Details and Pricing
Within these communities, posts show dark colored parcels with postal service stickers, stating to contain new batches. One communication stated: “It took eight of us to load them this morning.”
Customers can choose between dry substance containers, mixed at residence with purified liquid, or ready-to-use injectors typically priced at £160 for 20 milligrams. When questioned how long a pen should be used, vendors give conflicting responses varying between a several days to “depends on your body”.
Platform Moderation and Safety Actions
A representative for the messaging service stated it actively monitored dangerous material on its service including content that promoted the “misuse of controlled medications”. The company added that it eliminated “millions of pieces of harmful content each day”.
Medical Professional Cautions
“Individuals are administering materials they can’t verify. Although the science behind retatrutide is sound, these digital products may not contain what they advertise,” stated a pharmacy expert, the director of pharmacy at Chemist4U.
A medical professional of Asda Online Doctor connected the increase in demand to current price rises for approved weight-loss medications such as Mounjaro. “With costs rising, individuals are turning to online platforms. But counterfeit injections are extremely dangerous. You can’t be certain what’s inside or whether the environment they were produced in was clean,” she said.
Her team has previously seen patients injured by self-injection from unverified suppliers. “We understand the frustration, but buying from messaging apps or communication platforms is taking chances with your health,” said the doctor. “These substances could be contaminated or improperly measured.”
Manufacturer Statement
A spokesperson from the pharmaceutical company said retatrutide was in third stage research studies and had not been evaluated or approved by any regulatory agency globally. “Therefore at this point no one can market [it] for human use,” they said, adding that any product “falsely representing itself as a company investigational substance not yet approved … may subject users to possibly significant medical dangers”.
